Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) is one of the 11 Best Short-Term Stocks to Invest in.
A definitive merger agreement announced in the first week of August drives a short-term surge in the stocks’ performance.
A scientist in a lab coat, holding a beaker of a biopharmaceutical creation.
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on radioimmunotherapy and antibody-based oncology treatments. The company’s lead product, DANYELZA® (naxitamab-gqgk), is the first FDA-approved therapy for relapsed or refractory high-risk neuroblastoma in bone or bone marrow. Operating from New Jersey, the company also advances a robust pipeline of investigational cancer therapies.
On August 5, 2025, SERB Pharmaceuticals agreed to acquire Y-mAbs Therapeutics, Inc. in an all-cash transaction valued at approximately $412 million. SERB will commence a tender offer to purchase all outstanding shares of the company’s common stock for $8.60 per share in cash. This offer represents an approximate 105% premium to Y-mAbs Therapeutics, Inc.’ closing share price on August 4, 2025, the last full trading day before the transaction announcement.
The acquisition includes DANYELZA, Y-mAbs Therapeutics, Inc.’ lead commercial oncology asset. SERB intends to use it for broadening its existing Rare Oncology portfolio and expanding its investment in the U.S. market.
Y-mAbs Therapeutics, Inc.’s stock price soared by 71.43% this week, gaining a dramatic rebound after a 26.80% yearly drop, making it one of the best short-term biotech investments.
READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon
Disclosure. None.
